<DOC>
	<DOCNO>NCT02133352</DOCNO>
	<brief_summary>This single center , open-label trial design assess safety efficacy ranolazine ( Ranexa ) patient pulmonary hypertension associate leave ventricular diastolic dysfunction . All patient receive active drug . The study include screening period , 6 month treatment period follow period . Eligible patient provide informed consent meet inclusion/exclusion criterion enrol study . There neither proven therapy patient diastolic dysfunction-associated pulmonary hypertension patient diastolic dysfunction alone . Ranolazine , inhibitor cardiac repolarization ( sodium channel ) , could represent new effective treatment entity .</brief_summary>
	<brief_title>Study Ranolazine Treatment Pulmonary Hypertension Associated With Diastolic Left Ventricular Dysfunction</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Ventricular Dysfunction</mesh_term>
	<mesh_term>Ventricular Dysfunction , Left</mesh_term>
	<mesh_term>Ranolazine</mesh_term>
	<criteria>Written consent prior study procedure Men woman , age 18 75 year Suspicion Pulmonary Hypertension echo ( RVSP ≥ 50mmHg ) diagnosis Pulmonary Hypertension cardiac cath ( mPAP ≥25 mmHg rest ) LVEF ≥50 % , ( ECHO , radionuclide imaging , cardiac cath ) 6MWT distance ≥150m ≤450m time point within Screening Period NYHA/WHO functional class IIIII RHC measurement Study Day 1 : 1 ) mean pulmonary artery pressure ( MPAP ) ≥25 mmHg ; 2 ) pulmonary artery occlusion pressure ( PAOP ) ≥18 mmHg ≤30 mmHg ; 3 ) pulmonary artery diastolic pressure ( PADP ) PAOP ≤10 mmHg Presence history follow cardiovascular comorbidities condition : Hypotension Screening ( define rest SBP≤90mmHg ) . Hypertension Screening ( define rest SBP ≥200mmHg ) , Unstable cardiovascular disease include paroxysmal atrial fibrillation unstable angina , Amyloidosis , hypertrophic obstructive cardiomyopathy , restrictive cardiomyopathy , constrictive pericarditis , History myocardial infarction , coronary artery bypass graft surgery , percutaneous cardiac intervention , Significant valvular heart disease , Cerebrovascular accident transient ischemic attack Exercise tolerance limit noncardiac cause ( exerciseinduced asthma , malignancy , obesity , musculoskeletal disorder ) . Clinically significant psychiatric , addictive ( DSMIV criterion ) , neurologic disease condition would compromise his/her ability give inform consent , participate fully study , prevent adherence protocol Any condition comorbidity , opinion Investigator , would compromise his/her ability give inform consent , participate fully study , prevent adherence protocol Clinically significant laboratory abnormality , include : Positive Hep B surface antigen Hep C antibody , Positive HIV test within one year Study Day 1 , Serum alanine aminotransferase ( ALT ) ≥ 2.0 x ULN , Total bilirubin ≥ 1.2 x ULN ( unless evidence Gilbert 's syndrome ) . Serum creatinine ≥ 2.5mg/dL ( calculate creatinine clearance less equal 30mL/min ) . Hemoglobin le equal 10g/dL ( subject may qualify study follow diagnosis treatment anemia , anemia due iron and/or vitamin deficiency ) . Patients moderate severe hepatic impairment ( ChildPugh Classes B C ) require hemidialysis . Subject receive investigational medication within 30 day prior Screening Prior treatment ranolazine Pregnancy lactation Women childbearing potential men without vasectomy use barrier method contraception Subject presence , history , malignancy require significant medical intervention within precede 3 month and/or likely result death within next 2 year ( exception basal cell , nonmetastatic squamous cell carcinoma skin , carcinoma insitu cervix ) Treatment pulmonary hypertension epoprostenol ( Flolan ) , treprostinil ( Remodulin ) , iloprost ( Ventavis ) , bosentan ( Tracleer ) , ambrisentan ( Letairis ) , sildenafil ( Revatio ) , tadalafil ( Adcirca ) . The use sildenafil , tadalafil , vardenafil prohibit reason within 7 day hemodynamic assessment Days 1 180 ) . Patients QTc &gt; 500 msec baseline Treatment potent CYP3A inhibitor , include ketoconazole , itraconazonle , clarithromycin , nefazodone , nelfinavir , indinavir , &amp; saquinavir Treatment CYP3A inducer , include rifampin , rifabutin , rifapentin , phenobarbital , phenytoin , carbamazepine , St. John 's wort .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>pulmonary hypertension</keyword>
	<keyword>diastolic dyfunction</keyword>
</DOC>